Peter Jenkin is a Dermatology physician. OpenAlex indexes 23 publications with 642 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
87 Mcgregor St Ste 2100
Manchester, NH 031023767
Telephone
603-626-7546Provider last certified this registry record 17 Sept 2024.
Clinical trials
- Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)
Sponsor: Psoriasis Research Institute of Guangzhou
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202510 payments
- GENZYME CORPORATIONProgram year20253 payments
- Janssen Biotech, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
30.1%Other antiinfectives and antiseptics30.1%Ciclopirox100%Part D≥63 patientsAnti-infectives
29.8%Azole Antifungal25.6%Ketoconazole100%Part D≥49 patientsTetracycline-class Drug4.2%Doxycycline Monohydrate100%Part D<11 patientsRespiratory
13%Corticosteroid9%Mometasone Furoate100%Part D≥20 patientsRNA Synthetase Inhibitor Antibacterial3.9%Mupirocin100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 52803 TC Cream® is a Novel Botanical Topical Product for the Treatment of Psoriasis
Journal of the American Academy of Dermatology
2024 - Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
Journal of Allergy and Clinical Immunology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”